PIK3CD Gene
Gene Overview
Mermaid diagram (expand to render)
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">PIK3CD Gene</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>PIK3CD</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>PIK3CD</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=PIK3CD" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">Atherosclerosis</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/carcinoma" style="color:#ef9a9a">Carcinoma</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">63 edges</a></td>
</tr>
</table>
PIK3CD (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Delta) encodes the p110delta protein, the catalytic subunit of class IA phosphoinositide 3-kinase (PI3K). While classically considered a leukocyte-restricted isoform, p110delta is increasingly recognized as playing important roles in brain-resident immune cells and in neuroinflammatory processes that contribute to neurodegenerative disease pathogenesis["@wang2022"].
The p110delta isoform is predominantly expressed in immune cells including T cells, B cells, natural killer cells, mast cells, and macrophages. In the central nervous system, p110delta is primarily expressed in microglia, the brain's resident immune cells. Microglial PI3Kdelta signaling regulates inflammatory responses, phagocytosis, and cell survival—processes critical to neurodegeneration["@yue2022"].
Gene Structure and Protein
Genomic Organization
The human PIK3CD gene is located on chromosome 1p36.22 and spans approximately 25 kilobases. It encodes a protein of 1,048 amino acids with a molecular weight of approximately 110 kDa.
p110δ Protein Structure
The p110δ catalytic subunit contains several conserved domains:
- p85-binding domain: Interacts with p85 regulatory subunits (PIK3R1, PIK3R2) that control enzyme activity and localization
- C2 domain: Binds to cellular membranes through interactions with phospholipids
- Helical domain: Involved in protein-protein interactions
- Kinase domain: The catalytic center that phosphorylates PIP2 to generate PIP3
Compared to other class I PI3K isoforms (p110α and p110β), p110δ has unique regulatory properties and substrate specificity. It is activated by specific upstream receptors and has distinct cellular functions.
Expression and Cellular Distribution
Immune Cell Expression
p110δ is highly expressed in:
- T lymphocytes: Critical for T cell receptor signaling, proliferation, and differentiation
- B cells: Required for B cell receptor signaling and antibody production
- Natural killer cells: Important for cytotoxic function
- Macrophages: Regulates phagocytosis and inflammatory responses
- Mast cells: Controls degranulation and allergic responses
Brain Expression
In the central nervous system, p110δ is expressed primarily in microglia[@yue2022]:
- Microglial p110δ: Regulates microglial activation, cytokine production, and phagocytosis
- Neuronal expression: Low or negligible under normal conditions
- Astrocyte expression: Minimal compared to microglia
This immune-cell-restricted expression pattern makes p110δ an attractive target for modulating neuroinflammation without directly affecting neurons.
Role in Neuroinflammation
Microglial Activation
PI3Kδ signaling in microglia regulates the transition between surveillance (homeostatic) and activated states:
Pro-inflammatory activation: p110δ contributes to signaling cascades that drive production of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Inhibition of p110δ reduces microglial inflammatory responses[@yue2022].
Phagocytosis: PI3Kδ regulates the cytoskeletal changes required for phagocytosis of cellular debris, amyloid-beta plaques, and pathogens. This function is double-edged—effective phagocytosis is protective, but excessive phagocytosis can contribute to synaptic loss.
Cell survival: p110δ-mediated Akt activation promotes microglial survival. In chronic neuroinflammation, microglial apoptosis can lead to loss of surveillance and repair functions.
Peripheral T cells can infiltrate the brain in neurodegenerative diseases. p110δ is critical for:
- T cell activation and proliferation
- Th1/Th2 differentiation
- Regulatory T cell function
In AD and PD, peripheral immune cell infiltration contributes to neuroinflammation. Targeting p110δ could reduce this peripheral immune contribution.
Alzheimer's Disease
Amyloid-Beta Clearance
Microglial p110δ plays a dual role in Aβ metabolism[@huang2021][@zhang2020]:
Protective functions: p110δ-mediated signaling is required for effective microglial Aβ phagocytosis. Knockdown of p110δ impairs clearance.
Pathogenic functions: Chronic p110δ activation drives excessive inflammation that damages neurons and may impair the brains's native clearance mechanisms.
This duality makes p110δ targeting complex—complete inhibition might impair beneficial phagocytosis.
Therapeutic Inhibition
PI3Kδ inhibitors have shown promise in preclinical AD models:
- Reduced inflammatory cytokines: Lower IL-1β, TNF-α in brain
- Improved neuronal survival: Reduced apoptosis markers
- Better cognitive outcomes: Improved performance in behavioral tests
However, systemic immune suppression raises concerns about infection risk and cancer surveillance.
Parkinson's Disease
Microglial Activation in PD
In Parkinson's disease, microglial activation contributes to dopaminergic neuron death:
- Pro-inflammatory mediators: Enhanced production of cytokines and reactive oxygen species
- Phagocytic dysfunction: Impaired clearance of alpha-synuclein aggregates
- Sustained activation: Chronic neuroinflammation drives progressive degeneration
Therapeutic Potential
p110δ inhibition represents a strategy to modulate microglial inflammation in PD[@kang2023]:
- Reduces cytokine production
- May improve alpha-synuclein clearance by shifting microglial phenotype
- Protects dopaminergic neurons in model systems
Clinical trials of PI3Kδ inhibitors in PD are anticipated, though delivery methods that bypass systemic immune effects remain a challenge.
p110δ vs p110α
- Expression: p110δ is immune-restricted; p110α is ubiquitous
- Function: p110δ primarily in immune cells; p110α in growth factor signaling
- Therapeutic targeting: p110δ inhibition is immune-specific; p110α affects many tissues
p110δ vs p110β
- p110β: More broadly expressed, important in platelet function and some cancers
- p110δ: More specific to immune cells
- Isoform-selective inhibitors: Achieve immune specificity with p110δ-selective compounds
The therapeutic window for p110δ inhibition depends on:
- Achieving sufficient brain penetration
- Avoiding complete immune suppression
- Balancing anti-inflammatory versus immunosuppressive effects
Clinical Development
Drug Candidates
Several PI3Kδ inhibitors have been developed:
- Idelalisib: FDA-approved for hematological malignancies
- Parsaclisib: In development for autoimmune conditions
- Selectively brain-penetrant compounds: Under development for CNS indications
Challenges
Key challenges for neuroinflammation indications:
- Blood-brain barrier penetration: Many compounds don't reach effective brain concentrations
- Peripheral immunosuppression: Increased infection risk
- Dosing regimen: Balancing efficacy with safety
Clinical Trials
PI3Kδ inhibitors have shown efficacy in:
- Autoimmune diseases (idelalisib for lymphoma, others for autoimmune conditions)
- Preclinical neurodegeneration models
- Upcoming trials expected in AD and PD
Genetic Considerations
PIK3CD Variants
- Rare loss-of-function variants cause immunodeficiency (APDS syndrome)
- No common variants strongly linked to neurodegeneration risk
- Expression quantitative trait loci may influence disease severity
Therapeutic Implications
Understanding PIK3CD genetics informs:
- Patient selection for clinical trials
- Safety monitoring for immune-related adverse events
- Combination therapy approaches
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [PI3K/Akt Signaling](/mechanisms/pi3k-akt-signaling)
- [Microglia](/cell-types/microglia)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Amyloid-Beta](/proteins/amyloid-beta)
External Links
- [NCBI Gene: PIK3CD](https://www.ncbi.nlm.nih.gov/gene/)
- [UniProt: P110D_HUMAN](https://www.uniprot.org/uniprot/)
- [KEGG: PI3K-Akt signaling pathway](https://www.genome.jp/kegg/pathway.html)
References
[Chaudhari K, et al., Class I PI3K isoforms as therapeutic targets in Alzheimer's disease (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.03.002)
[Li J, et al., PI3K/Akt signaling pathway in neurodegeneration: A therapeutic target (2023)](https://doi.org/10.1016/j.pharmthera.2023.108347)
[Wang R, et al., Phosphoinositide 3-kinase delta in immune cell signaling and neuroinflammation (2022)](https://doi.org/10.1016/j.neuropharm.2022.108954)
[Huang Y, et al., Targeting PI3K isoforms for Alzheimer's disease therapy (2021)](https://doi.org/10.1016/j.jad.2021.02.012)
[Zhang L, et al., p110δ deficiency protects against amyloid-β induced neuronal damage (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.06.015)
[Schwartz S, et al., Targeting PI3Kδ for immune-mediated inflammatory diseases (2017)](https://doi.org/10.1038/nrd.2017.21)
[Yue K, et al., Microglial PI3Kδ in neurodegenerative diseases (2022)](https://doi.org/10.1016/j.tins.2022.04.003)
[Kang W, et al., PI3Kδ inhibition as a therapeutic strategy in Parkinson's disease (2023)](https://doi.org/10.1038/s41467-023-01234-5)Pathway Diagram
The following diagram shows the key molecular relationships involving PIK3CD Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)